

Vagal Blocking for the Treatment of Obesity Delivered Using the Fully Implantable Maestro Rechargeable System:  
12 Month Results

**DESCRIPTION**

<b>Prospective, multi-center, safety and efficacy assessment</b>	33 subjects <i>n=30 subjects at 12 months</i> 5 centers
<b>4 and 12 weeks follow-up, 6 and 12 months follow-up</b>	

**RESULTS & SUMMARY**

vBloc was associated with weight loss and a promising safety profile.

- + 3 SAEs related to implant procedure
- + No SAEs related to the device or therapy

Parameters	Wk 4	Wk 12	Mo 6	Mo 12
<b>EWL (%)</b>	12.3	20	24	25

To learn more, visit [www.vBloc.com](http://www.vBloc.com)

The Maestro® Rechargeable System is indicated for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m<sup>2</sup>, or a BMI of 35 to 39.9 kg/m<sup>2</sup> with one or more obesity related co-morbid conditions, and have failed at least one supervised weight management program within the past five years. The device should not be implanted in patients with cirrhosis, portal hypertension, esophageal varices or a significant hiatal hernia; patients for whom magnetic resonance imaging (MRI) or diathermy is planned; patients with an implanted electrical medical device or gastrointestinal device or prosthesis.

The most common related adverse events include pain, heartburn, nausea, dysphagia, eructation, and abdominal cramping.

Carefully read the product instruction manuals for complete safety information.

vBloc and Maestro are trademarks of EnteroMedics, Inc.

© 2015 EnteroMedics, Inc. All rights reserved.